Cells from USC109, obtained from a patient with FLT3-ITD AML at diagnosis exhibited a significant decrease in cell viability at 72 hours in FLT3-A192 and Co-Assembled compared with A192 but not in CD99-A192 (FLT3-A192 vs. A192, P = 0.005, 19% decrease; Co-Assembled vs. A192, P = 0.0008, 24% decrease; Co-Assembled vs. CD99-A192, P = 0.0009, 24% decrease; Fig. 4J). The gene discussed is FLT3; the disease is acute myeloid leukemia.